drugset / Trial / NCT00059644

Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease

NCT00059644 ↗

Phase 3 Terminated 560 enrolled Tanabe Pharma Corporation
RandomizedParallel-groupDouble-blindTreatment

Summary

Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD). This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.

Timeline

Start
2001-07
Primary completion
—
Completion
2004-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Ecraprost Small molecule — —